Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
NCT07175428 · View on ClinicalTrials.gov ↗
Study Summary
This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how well REGN7508 and REGN9933 work in patients that get medicine for their atrial fibrillation. The bleeding effects of REGN7508 and REGN9933 will be compared to another medicine (apixaban), which is available on the market to treat and prevent formation of blood clots. The study is looking at several other research questions, including: * What side effects may happen from taking REGN7508 or REGN9933 * How well do the study drugs reduce the risk of having a stroke * How much of REGN7508 or REGN9933 is in the blood at different times * Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the drugs less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG Apixaban
- DRUG REGN7508
- DRUG REGN9933
Study Locations (20)
California
- Mission Cardiovascular Research Institute — Fremont
- National Institute of California Heart and Vein Specialists — Huntington Beach
- Profound Research LLC at Southern California Heart Specialists — Pasadena
- Empire Clinical Research — Pomona
- Northbay Clinical Research Center — Santa Rosa
- Cardiology Associates Medical Group — Ventura
- Interventional Cardiology Medical Group — West Hills
Florida
- Nouvelle Clinical Research LLC — Cutler Bay
- Inpatient Research Clinic LLC — Miami Lakes
- Cardiovascular Center of Sarasota Foundation for Research and Education — Sarasota
- Clinical Site Partners, LLC DBA Flourish Research — Winter Park
Indiana
- Indiana University — Indianapolis
- Blue Coast Research Center, LLC — Indianapolis
- Franciscan Physician Network, Indiana Heart Physicians — Indianapolis
- Reid Physician Associates — Richmond
Alabama
- SEC Clinical Research — Dothan
- Eastern Shore Research Institute — Fairhope
Georgia
- Health Sciences Research Building II — Atlanta
- NSC Research, Inc — Johns Creek
Louisiana
- Monroe Research, LLC — West Monroe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2025-10-20 |
| Est. Completion | 2027-04-21 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07175428
The ClinicalTrials.gov registry entry for NCT07175428 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 290 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Atrial Fibrillation (AF) appearing as the primary indexed condition, and to 3 interventions — of which Apixaban is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07175428 reports 20 study locations spanning 6 distinct geographic areas — top geographies include California, Florida, Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07175428 about?
NCT07175428 is a clinical study titled "Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation". This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillati...
What is the current status of trial NCT07175428?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,200 participants. The study started on 2025-10-20. Estimated completion is 2027-04-21.
What conditions does trial NCT07175428 study?
This clinical trial studies the following conditions: Atrial Fibrillation (AF). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07175428?
The interventions under investigation include: Apixaban (DRUG), REGN7508 (DRUG), REGN9933 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07175428?
This trial is sponsored by Regeneron Pharmaceuticals, which has 290 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07175428 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.